Northern New England Clinical and Translational Research Network

新英格兰北部临床和转化研究网络

基本信息

  • 批准号:
    10681809
  • 负责人:
  • 金额:
    $ 136.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-07 至 2024-09-30
  • 项目状态:
    已结题

项目摘要

The long-term goal of the Northern New England Clinical and Translational Research Network (NNE-CTR), composed of MaineHealth, the University of Vermont, and the University of Southern Maine, is to sustain a clinical and translational research infrastructure that supports improvements in community health for northern New England inhabitants. Maine and Vermont have the oldest populations in the U.S. and that, coupled with rurality, predisposes residents to a range of disorders ranging from cancer to substance use disorders, food insecurity, obesity, diabetes and cardiovascular disease. In addition, northern New England has a growing underserved immigrant population, as well as a Native American population. Our communities have been challenged by the Covid-19 pandemic, and we are addressing these challenges by linking primary care practice centers with academic centers and developing innovative approaches to community-based research. During our first four years, the NNE-CTR has built a strong foundation for clinical research. We partnered with the oldest regional practice-based research network (PBRN), the Dartmouth Co-Op, and actively supported successful NIH program applications, including two COBREs, two NCI program grants, an infrastructure grant for a new Center for Biomedical Shared Resources, and a HRSA grant to build on the opioid treatment model pioneered in Vermont. The NNE-CTR PI is playing a leadership role in coordinating a national CTR network, including the CTR National COVID Cohort Collaborative (N3C), a registry to share clinical data on Covid-19 nationally, and the NIH-sponsored RECOVER trial, which will define the long-term sequelae of Covid-19. In this renewal, we plan to expand our collaborations both regionally and nationally, strengthen our PBRN, and embrace cultural diversity. We will strengthen Core resources that include: the Biostatistics, Epidemiology and Research Design Core, which will improve data capability and research navigation services; the Professional Development Core, which will offer an array of new educational and mentorship opportunities; the Pilot Projects Program, which will provide new and flexible funding mechanisms to offer more support for community-based projects; the Translational Research and Technology Core, offering state-of-the-art technologies and training for new investigators, and the Community Engagement and Outreach Core, which will build stronger bridges to underserved communities. We propose three specific aims: 1-Expand infrastructure and resources to address clinical and translational research needs in northern New England; 2- Strengthen clinical and translational research that addresses health equity and disparities encountered by at- risk populations, including expansion of clinical trial access, telehealth, and mentored training programs for new investigators; and 3-Accelerate regional and national collaborative initiatives within the IDeA networks and through NIH such as N3C and RECOVER. In sum, we will strengthen the NNE-CTR through continuous learning and improvement supported by the principles of diversity, inclusion, and equity.
北新英格兰临床和转化研究网络(NNE-CTR)的长期目标, 由 MaineHealth、佛蒙特大学和南缅因大学组成,旨在维持 支持改善北部社区健康的临床和转化研究基础设施 新英格兰居民。缅因州和佛蒙特州拥有美国最古老的人口,再加上 农村地区的居民容易患上一系列疾病,从癌症到药物滥用、食物 不安全感、肥胖、糖尿病和心血管疾病。此外,新英格兰北部也有不断增长的 服务不足的移民人口以及美洲原住民人口。我们的社区已经 受到 Covid-19 大流行的挑战,我们正在通过将初级保健联系起来来应对这些挑战 实践中心与学术中心,并开发基于社区的研究的创新方法。 在最初的四年里,NNE-CTR 为临床研究奠定了坚实的基础。我们与以下机构合作: 最古老的区域实践研究网络 (PBRN),达特茅斯合作社,并得到积极支持 成功的 NIH 计划申请,包括两项 COBRE、两项 NCI 计划拨款、一项基础设施拨款 建立新的生物医学共享资源中心,以及 HRSA 拨款以建立阿片类药物治疗模型 首创于佛蒙特州。 NNE-CTR PI 在协调国家 CTR 网络方面发挥着领导作用, 包括 CTR National COVID Cohort Collaborative (N3C),这是一个共享 Covid-19 临床数据的注册中心 以及 NIH 赞助的 RECOVER 试验,该试验将确定 Covid-19 的长期后遗症。在 此次更新,我们计划扩大区域和国家范围内的合作,加强我们的 PBRN,以及 拥抱文化多样性。我们将加强核心资源,包括:生物统计学、流行病学和 研究设计核心,将提高数据能力和研究导航服务;专业人士 发展核心,将提供一系列新的教育和指导机会;飞行员 项目计划,将提供新的、灵活的资助机制,为 以社区为基础的项目;转化研究和技术核心,提供最先进的 为新研究者提供技术和培训,以及社区参与和外展核心, 将为服务欠缺的社区建立更牢固的桥梁。我们提出三个具体目标: 1-扩展 满足新英格兰北部临床和转化研究需求的基础设施和资源; 2- 加强临床和转化研究,解决健康公平问题和以下人群遇到的差异: 风险人群,包括扩大临床试验机会、远程医疗和指导培训计划 新调查员; 3-加速 IDeA 网络内的区域和国家合作举措 以及通过 NIH,例如 N3C 和 RECOVER。总而言之,我们将通过不断加强 NNE-CTR 在多样性、包容性和公平原则的支持下学习和进步。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CLIFFORD JAMES ROSEN其他文献

CLIFFORD JAMES ROSEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CLIFFORD JAMES ROSEN', 18)}}的其他基金

Understanding Factors Influencing COVID-19 Testing and Vaccination in Immigrant Low-income and Homeless Populations and Testing Targeted Interventions
了解影响移民低收入和无家可归人群的 COVID-19 检测和疫苗接种的因素以及测试有针对性的干预措施
  • 批准号:
    10413438
  • 财政年份:
    2021
  • 资助金额:
    $ 136.41万
  • 项目类别:
FSH - an Aging Hormone?
FSH——一种衰老激素?
  • 批准号:
    10356114
  • 财政年份:
    2019
  • 资助金额:
    $ 136.41万
  • 项目类别:
FSH - an Aging Hormone?
FSH——一种衰老激素?
  • 批准号:
    10112794
  • 财政年份:
    2019
  • 资助金额:
    $ 136.41万
  • 项目类别:
FSH - an Aging Hormone?
FSH——一种衰老激素?
  • 批准号:
    10577830
  • 财政年份:
    2019
  • 资助金额:
    $ 136.41万
  • 项目类别:
Northern New England Clinical and Translational Research Network
新英格兰北部临床和转化研究网络
  • 批准号:
    10675577
  • 财政年份:
    2017
  • 资助金额:
    $ 136.41万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10871636
  • 财政年份:
    2017
  • 资助金额:
    $ 136.41万
  • 项目类别:
Physiology Core
生理学核心
  • 批准号:
    10711694
  • 财政年份:
    2017
  • 资助金额:
    $ 136.41万
  • 项目类别:
Northern New England Clinical and Translational Research Network-Equipment
新英格兰北部临床和转化研究网络设备
  • 批准号:
    10797663
  • 财政年份:
    2017
  • 资助金额:
    $ 136.41万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10891897
  • 财政年份:
    2017
  • 资助金额:
    $ 136.41万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10505150
  • 财政年份:
    2017
  • 资助金额:
    $ 136.41万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 136.41万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 136.41万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 136.41万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 136.41万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 136.41万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 136.41万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 136.41万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 136.41万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 136.41万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 136.41万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了